HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Gerald F Watts Selected Research

Apolipoprotein A-II (Apolipoprotein A2)

4/2016ApoA-II HDL Catabolism and Its Relationships With the Kinetics of ApoA-I HDL and of VLDL1, in Abdominal Obesity.
6/2012Apolipoprotein A-II: evaluating its significance in dyslipidaemia, insulin resistance, and atherosclerosis.
5/2010Association of apolipoprotein M with high-density lipoprotein kinetics in overweight-obese men.
10/2009Effect of weight loss on HDL-apoA-II kinetics in the metabolic syndrome.
8/2008HDL metabolism in context: looking on the bright side.
1/2007Dietary plant sterols supplementation does not alter lipoprotein kinetics in men with the metabolic syndrome.
7/2006Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Gerald F Watts Research Topics

Disease

117Cardiovascular Diseases (Cardiovascular Disease)
06/2022 - 02/2002
47Hyperlipoproteinemia Type II (Familial Hypercholesterolemia)
06/2022 - 03/2002
45Coronary Artery Disease (Coronary Atherosclerosis)
11/2022 - 01/2001
44Metabolic Syndrome (Dysmetabolic Syndrome X)
11/2021 - 01/2003
42Dyslipidemias (Dyslipidemia)
01/2022 - 08/2002
42Type 2 Diabetes Mellitus (MODY)
01/2022 - 12/2002
38Atherosclerosis
01/2022 - 05/2002
34Insulin Resistance
01/2017 - 02/2002
29Obesity
07/2022 - 05/2002
28Coronary Disease (Coronary Heart Disease)
01/2022 - 02/2003
22Hypertension (High Blood Pressure)
07/2022 - 11/2002
20Abdominal Obesity
04/2016 - 02/2002
17Hypertriglyceridemia
01/2020 - 03/2006
15Weight Loss (Weight Reduction)
11/2021 - 02/2003
15Hypercholesterolemia
01/2021 - 03/2002
13Inflammation (Inflammations)
01/2021 - 07/2002
12Homozygous Familial Hypercholesterolemia
01/2020 - 08/2013
11Chronic Renal Insufficiency
01/2022 - 09/2009
10Myocardial Infarction
01/2022 - 03/2011
8Pancreatitis
03/2022 - 11/2013
8Non-alcoholic Fatty Liver Disease
01/2017 - 02/2008
7Inborn Genetic Diseases (Disease, Hereditary)
01/2022 - 02/2015
7Psychotic Disorders (Schizoaffective Disorder)
01/2019 - 01/2013
7Overweight
12/2018 - 01/2003
6Acute Coronary Syndrome
01/2022 - 08/2013
6Stroke (Strokes)
10/2021 - 10/2004
6Hyperlipidemias (Hyperlipidemia)
11/2020 - 02/2003
5Diabetes Mellitus
11/2022 - 08/2012
5Aortic Valve Stenosis (Aortic Stenosis)
01/2022 - 05/2018
5Body Weight (Weight, Body)
08/2014 - 10/2009
4Xanthomatosis (Xanthoma)
01/2018 - 12/2013
4Muscular Diseases (Myopathy)
01/2018 - 02/2008
3Vascular Calcification
11/2022 - 10/2018
3Peripheral Arterial Disease
01/2020 - 01/2017

Drug/Important Bio-Agent (IBA)

69LDL CholesterolIBA
01/2022 - 02/2002
68Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
07/2022 - 01/2001
64Lipoproteins (Lipoprotein)IBA
03/2022 - 02/2002
60LipidsIBA
11/2022 - 06/2002
58Triglycerides (Triacylglycerol)IBA
03/2022 - 02/2002
54oxidized low density lipoproteinIBA
01/2022 - 02/2003
52Lipoprotein(a)IBA
07/2022 - 03/2014
42CholesterolIBA
01/2021 - 03/2002
34LDL Lipoproteins (beta Lipoproteins)IBA
06/2022 - 03/2002
33HDL CholesterolIBA
01/2022 - 01/2001
29Apolipoproteins B (ApoB)IBA
01/2020 - 03/2002
28ApolipoproteinsIBA
11/2022 - 01/2004
25Apolipoprotein B-100 (Apo B 100)IBA
11/2021 - 02/2002
21Fenofibrate (CiL)FDA LinkGeneric
01/2021 - 12/2002
19Apolipoprotein A-I (Apolipoprotein A1)IBA
11/2021 - 03/2003
17Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA
06/2022 - 11/2002
17Fibric Acids (Fibrates)IBA
03/2022 - 01/2001
17Insulin (Novolin)FDA Link
01/2019 - 08/2002
16HDL LipoproteinsIBA
11/2021 - 02/2004
13Apolipoprotein C-IIIIBA
12/2021 - 08/2002
12LDL Receptors (LDL Receptor)IBA
07/2022 - 03/2002
12Fish OilsIBA
11/2021 - 06/2002
11Ezetimibe (Zetia)FDA Link
03/2022 - 05/2010
11IsotopesIBA
11/2021 - 05/2002
11VLDL LipoproteinsIBA
11/2021 - 01/2003
10Apolipoprotein B-48IBA
12/2021 - 02/2003
10Fatty Acids (Saturated Fatty Acids)IBA
10/2016 - 12/2002
10Atorvastatin (Lipitor)FDA Link
11/2012 - 05/2002
9Pharmaceutical PreparationsIBA
01/2022 - 01/2004
9AdiponectinIBA
09/2013 - 09/2004
8CalciumIBA
11/2022 - 10/2018
8Niacin (Nicotinic Acid)FDA LinkGeneric
12/2016 - 01/2004
7Apolipoproteins AIBA
06/2022 - 07/2005
7Blood Glucose (Blood Sugar)IBA
12/2018 - 06/2011
7ChylomicronsIBA
12/2016 - 02/2003
7Apolipoprotein A-II (Apolipoprotein A2)IBA
04/2016 - 07/2006
6Apoprotein(a) (Apolipoprotein (a))IBA
06/2022 - 12/2010
6Proprotein Convertase 9IBA
03/2022 - 05/2016
6Peroxisome Proliferator-Activated Receptors (PPAR)IBA
07/2018 - 05/2008
6coenzyme Q10 (CoQ10)IBA
01/2018 - 05/2003
6BMS201038IBA
07/2017 - 08/2013
6C-Reactive ProteinIBA
03/2011 - 04/2002
6Interleukin-6 (Interleukin 6)IBA
05/2010 - 06/2002
5Antihypertensive Agents (Antihypertensives)IBA
10/2017 - 08/2012
5Rosuvastatin Calcium (Crestor)FDA Link
06/2015 - 02/2008
5Cholesterol Ester Transfer ProteinsIBA
09/2009 - 12/2002
4Apolipoproteins E (ApoE)IBA
11/2022 - 11/2012
4evolocumabIBA
01/2020 - 06/2014
4Glucose (Dextrose)FDA LinkGeneric
01/2019 - 03/2011
4PCSK9 InhibitorsIBA
01/2019 - 08/2013
4Proteins (Proteins, Gene)FDA Link
05/2017 - 02/2004
4Antipsychotic Agents (Antipsychotics)IBA
05/2016 - 06/2014
4Leucine (L-Leucine)FDA Link
10/2015 - 07/2006
4EnzymesIBA
09/2014 - 02/2004
4mipomersenIBA
08/2014 - 01/2012
4Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
03/2005 - 07/2002
3Biomarkers (Surrogate Marker)IBA
11/2022 - 05/2017
3CreatinineIBA
01/2022 - 06/2011
3Uric Acid (Urate)IBA
01/2021 - 06/2011
3LeptinIBA
01/2021 - 03/2005
3Probucol (Lorelco)FDA Link
01/2020 - 01/2014
3Monoclonal AntibodiesIBA
01/2019 - 12/2013

Therapy/Procedure

65Therapeutics
01/2022 - 08/2002
13Drug Therapy (Chemotherapy)
07/2019 - 01/2004
12Blood Component Removal (Apheresis)
01/2020 - 08/2013
5Secondary Prevention
02/2021 - 01/2001